استفاده از پلاسما حیوانی در برابر پاتوژن های عفونی در انسان
کد: G-1027
نویسندگان: Mehrshad Sadeghian © ℗, Sayed Ali Mousavinia
زمان بندی: زمان بندی نشده!
دانلود: دانلود پوستر
خلاصه مقاله:
خلاصه مقاله
Plasma therapy, particularly the use of convalescent plasma, has emerged as a significant therapeutic approach in combating infectious diseases in humans. This method utilizes plasma derived from recovered individuals, which contains antibodies against specific pathogens, offering passive immunity to recipients. Historically, convalescent plasma therapy has been employed during various viral outbreaks, including the Spanish flu and more recently during the COVID-19 pandemic. The application of convalescent plasma dates back over a century, with notable efficacy observed during the 1918 influenza pandemic. Reports indicated improvements in patient outcomes following plasma transfusions, suggesting that the antibodies present could neutralize the virus effectively. The mechanism by which this therapy operates involves the transfer of immunoglobulins from donors who have successfully fought off an infection, thereby enhancing the recipient's immune response against the same pathogen. In recent years, scientific interest has surged regarding the potential of animal-derived plasma therapies. For instance, studies have explored using equine and bovine plasma to treat various infectious diseases in humans. These animal sources can provide high titers of neutralizing antibodies, which may be particularly beneficial when human plasma is scarce or when rapid intervention is necessary. The use of animal plasma presents both opportunities and challenges; while it may offer a broader range of antibody profiles, concerns regarding immunogenicity and safety must be addressed. Clinical trials have demonstrated that convalescent plasma can reduce mortality rates in severe cases of viral infections such as Ebola and SARS-CoV-2. A systematic review highlighted that patients receiving high-titer convalescent plasma had significantly lower mortality rates compared to those who did not receive treatment. However, optimal timing and dosage remain critical factors influencing the success of this therapy. Administering plasma early in the course of infection appears to maximize its benefits. Animal plasma therapy represents a promising adjunctive treatment for infectious diseases in humans. While historical data supports its efficacy, ongoing research is essential to refine protocols and ensure safety. As we navigate future pandemics, leveraging both human and animal-derived plasma could play a pivotal role in enhancing our therapeutic arsenal against infectious pathogens.
کلمات کلیدی
Plasma therapy, Passive immunity, Immunoglobulin, Equine, Bovine, Viral infection
